In this study, we uncover that, in two neuroblastoma cell lines IMR-5 (wild-type p53) and SK-N-AS (mutant p53), CBN attenuates cell proliferation, angiogenesis, and invasion in a dose-dependent manner via inhibiting the AKT pathway and upregulating miR-34a, which targets E2F1. The gene discussed is TP53; the disease is neuroblastoma.